BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

CEO

Mr. Kenneth Mulvany

Karyawan

180

Negara

Luksemburg

ISIN

LU2355630455

WKN

000A3CTVP

Pencatatan

STU

2XA.STU

0 Comments

Bagikan pendapatmu

FAQ

Berapa harga saham Odyssey Acquisition. hari ini?▼

Harga saat ini dari 2XA.STU adalah €0,57 EUR — naik sebesar +7,2% dalam 24 jam terakhir. Pantau kinerja harga saham Odyssey Acquisition. lebih dekat di grafik.

Apa simbol saham Odyssey Acquisition.?▼

Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham Odyssey Acquisition. diperdagangkan dengan simbol 2XA.STU.

Berapa jumlah karyawan Odyssey Acquisition.?▼

Per September 04, 2026, perusahaan memiliki 180 karyawan.

Odyssey Acquisition. berada di sektor apa?▼

Odyssey Acquisition. beroperasi di sektor Kesehatan & Kebugaran.

Kapan Odyssey Acquisition. menyelesaikan split saham?▼

Odyssey Acquisition. belum melakukan split saham baru-baru ini.

Di mana kantor pusat Odyssey Acquisition.?▼

Kantor pusat Odyssey Acquisition. berlokasi di London, Luksemburg.